Kornimate/medical-research-clean huggingface dataset:
stabilization of trochanteric fracture using a screw-plate traumax

Conditions: Hip Fracture

Summary: the purpose of this study is to evaluate the stabilization of trochanteric fracture using a screw-plate traumax

hip fractures are a serious public health problem. the current incidence is projected to increase fourfold worldwide by the year 2050. this affliction is obviously linked to the aging of the population and the absence of a systematic prevention of osteoporosis. this leads to the creation of a minimally invasive, or ever percutaneous, implantable osteosynthesis material which associates : * the well-known reliability of osteosynthesis using screw-plate with barrel, * the safety of the fixation with surfix concept, locking the screws to the plate using lock-screws, * a modularity thanks to the choice between 3 sizes of barrel, * the creation of a simple material, easing the operative surgery by minimally invasive approach. the traumax answers to all those characteristics.

Eligibility criteria:
inclusion criteria: * man or woman * age \> 18 * with a trochanteric fracture whom surgeon advised the use of a screw-plate traumax exclusion criteria: * patient with an acute infection * patient with a major osseous deterioration which not allows a correct support of the screws in the bone * patient with an asa score of 4 or 5 * patient whom the time between the fracture and the surgery could be higher than 8 days

Keywords: mini-invasive dynamic screw-plate surfix lock-screw
nad+ augmentation in cardiac surgery associated myocardial injury trial

Conditions: Ischemia Reperfusion Injury; Myocardial Injury; Acute Kidney Injury

Summary: a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of oral nam for the prevention of acute kidney injury in patients undergoing on-pump cardiac surgery

this trial is a single-center, randomized, double-blind placebo-controlled trial of nam versus placebo in patients undergoing on-pump cardiac surgery. after screening and enrollment, patients will be stratified according to ckd status (egfr\<45 ml/min/m2) and surgical site and randomized in a 1:1 manner to receive either nam 3 grams or placebo on the day of surgery and post-surgical days one and two. the overall trial duration is planned for 42 months, consisting of 39 months of active recruitment and treatment period and three months of follow-up from the last patient enrolled.

Eligibility criteria:
inclusion criteria * informed consent before any study-related activities. * men or women \>18 years of age who are scheduled for non-emergent cardiac surgery procedures requiring cpb and are at increased risk for surgery-related adverse cardiovascular outcomes. procedures include: * cabg * aortic, mitral, tricuspid, or pulmonic valve replacement or repair * cabg with aortic, mitral, tricuspid, and/or pulmonic valve replacement risk factors for surgery related to adverse cardiovascular outcomes include one or more of the following: * valve surgery * egfr \< 45 ml/min/1.73m2 * documented lvef ≤ 35% within six months before surgery * documented history of heart failure * insulin-requiring diabetes * non-insulin-requiring diabetes and the presence of ≥+2 proteinuria on urinalysis (or equivalent on urine protein-to-creatinine ratio or urine albumin-to-creatinine ratio) * preoperative anemia (hemoglobin \<11g/dl for men and women) * history of prior cabg * age ≥65 exclusion criteria * preexisting aki within seven days before surgery as defined by kdigo stage ≥1 (serum creatinine-based) * kidney transplant status * off-pump cardiac surgery * esrd * emergent cardiac surgery * pregnancy * patient enrolled in competing research studies that may affect outcomes * patients held in an institution by legal or official order
safety and efficacy of mk0736 & mk0916 in patients with hypertension (high blood pressure)(0736-003)(completed)

Conditions: Hypertension

Summary: the objective of this study is to evaluate the safety and efficacy of two investigational drugs (mk-0736 and mk-0916) in lowering blood pressure and body weight in patients with hypertension (high blood pressure). this is an early phase trial and some specific protocol information is proprietary and not publicly available at this time. (full information is available to trial participants).

participants enrolled in the study will be separated into 2 strata based on baseline body mass index (bmi) assessments prior to being randomly assigned to study treatment. study will include a 24-week treatment period comprised of 2 phases, a and b, each of which will 12 weeks in duration.

Eligibility criteria:
inclusion criteria: * hypertension systolic blood pressure (sbp) \</= 160mm hg and diastolic blood pressure (dbp): 90-105mm hg exclusion criteria: * pre-menopausal women * patients currently taking more than two (2) blood pressure lowering medications * body mas index (bmi)\>40 kg/m2 (morbidly obese patients) * history of alcohol abuse (\<3 years) * history of diabetes,chronic kidney disease, active liver disease, recent heart attack or stroke
effects of self-myofascial release on hamstring flexibility in patients with non specific low back pain

Conditions: Nonspecific Low Back Pain

Summary: the aim of this preliminary study suggest the addition of self myofascial release to a therapeutic exercise program in reducing hamstring flexibility and would have additional effects on decreasing pain intensity in individuals with non specific low back pain.

there are different treatments that can affect the facial tissue, but mfr techniques have shown promising effects in reducing pain, improving flexibility and daily activities, these techniques involve specifically guided load long-duration mechanical forces to manipulate the myofascial complex (16). fascia is part of a body-wide tensional force "transmission system" as facial system is innervated by mechano receptors, that when manual pressure is applied may create a range of response via myofascial pathway by transmitting tensional force and decreasing muscle tension that facilitate movement and reduce pain, however in reviewing the literature, there is still theory and hypothesis in relation to the exact mechanism underlying the efficacy of facial manual therapy self myofascial release (smr) works under the same principle as myofascial release technique in which individual use their own body mass to exert pressure on soft tissues by tennis ball to the plantar surface of the foot and is widely used to increase flexibility and range of movement further along the posterior muscles of a proposed anatomy train.

Eligibility criteria:
inclusion criteria: * patients with nonspecific low back pain for at least 3 months. * \>20 degree active knee extension loss with hip in 90 degree of flexion * nprs \>3 * patients willing to participate and take treatment. exclusion criteria: * patients having severe orthopedic, neurological disease * patients having specific diagnose cause of low back pain (infection, tumor, lumbar spine fracture, radicular pain, cauda equina syndrome) * involvement in regular flexibility yoga program * recent(\<6 months) lower limb, spinal or soft tissue injuries * any integumentary contraindication to mfr

Keywords: hamstring flexibility non specific low back pain self myofascial release
return on investment on lap gastric bypass regarding quality of life

Conditions: Obesity

Summary: the purpose of this study is to investigate the cost of treatment and adverse efffects therof corresponds to quality of life improvements and expected wheightloss.


Eligibility criteria:
inclusion criteria: * bmi \> 35 * age 18-60 years exclusion criteria: * prior bariatric surgery * prior gastric surgery

Keywords: obesity bariatric surgery laparoscopic gastric bypass quality of life qaly
biomarkers for post-covid conditions

Conditions: COVID-19; SARS-CoV-2; Biomarkers; Post-acute COVID-19 Syndrome

Summary: the covid-19 infection affects humans differently. while some recover quickly and fully, others develop serious illnesses and late complications. the term late complications describe symptoms that last for 12 weeks or longer after covid-19 infection is detected. the aim of the present project is to investigate whether it is possible to identify genetic factors that occur more frequently in people suffering from covid-19 late complications than in those who do not develop late complications. the investigators aim to develop a genetic profile that identifies individuals at high risk for late complications of covid-19. number and nature of late complications will be analysed to identify patterns in the incidence of late complications associated with certain genetic traits. the study is designed as a case-control study and is expected to include 500 subjects between 18 and 65 years of age who at least 12 weeks ago tested positive for covid-19; 250 who suffer from late complications and 250 who have fully recovered.


Eligibility criteria:
inclusion criteria: * age 18 to 65 years * sars-cov-2 infection proven by a pcr test at least 12 weeks prior to inclusion * only cases: referred to the clinic of post-covid conditions located in region zealand, denmark exclusion criteria: * need of being on a respirator during infection with sars-cov-2 * only controls: complain about long covid 12 weeks or more after proven infection with sars-cov-2

Keywords: post-covid-19
efficiency and tolerance of rituximab (mabthéra) in bullous pemphigoid

Conditions: Bullous Pemphigoid

Summary: the aim of the study is to assess that it will be possible to control with a single cycle of rituximab patient with bullous pemphigoid.

the objective of this study is to assess the efficacy and tolerance of a single cycle of rituximab in control of bullous pemphigoid. the main objects are : 1. to assess that a single cycle of rituximab is able to control patient with corticosteroid-dependent bullous pemphigoid, 2. to avoid the use of corticosteroid in long time, 3. to evaluate duration of control disease and side effect with a single cycle of rituximab.

Eligibility criteria:
inclusion criteria: * age \>= 18 and \< 80 * karnofsky \>= 50% * bullous pemphigoid clinical indication * cortico-dependent bullous pemphigoid in relapse for the second time * contraception used in female patient * consent obtained from patient exclusion criteria: * localized bullous pemphigoid in relapse (\<400cm2) * pemphigoid of pregnancy * dermatosis with iga * pemphigoid with mucous damage * pregnant woman or nursing mother * woman able to have a baby and without contraception during the clinical trial period * age \ 80 * karnovsky \< 50% * significant disease or uncontrolled disease * serious antecedents of allergy or anaphylactic reaction with human monoclonal antibody * patient with depletion lymphocytic treatment or with initial rituximab treatment * unstable angina or ischemic heart disease * cardiac insufficiency * cardiac rhythm trouble uncontrolled * evolutive infection * immunodepression * neutrophil polynuclear in blood \< 1.5 g/l and /or platelet blood concentration \< 75g/l * positive hiv serology * positive hepatitis b and / or c serology * concomitant immunodepressor treatment able to induce depletion lymphocytic treatment * no consentment * antecedent of serious chronic or recurrent infection or other underlying pathology able to induce serious infection * antecedent of deep tissue infection occurred the previous year of inclusion

Keywords: bullous pemphigoid mabthera
an active approach to treat amblyopia: video game play

Conditions: Amblyopia

Summary: amblyopia, a developmental abnormality that impairs spatial vision, is a major cause of vision loss, resulting in reduced visual acuity and reduced sensitivity to contrast. this study uses psychophysical measures to study neural plasticity in adults with amblyopia.

amblyopia, a developmental abnormality that impairs spatial vision, is a major cause of vision loss, resulting in reduced visual acuity and reduced sensitivity to contrast. our previous findings (see citations) show that the adult amblyopic brain is still plastic and malleable, suggesting that active approach is potential useful in treating amblyopia. the goal of this project is to assess the limits and mechanisms of neural plasticity in amblyopic spatial vision. this study uses psychophysical measures to study neural plasticity in adults with amblyopia. research participants will be asked to play video games with the amblyopic eye for a period of time. a range of visual functions will be monitored during the course of treatment.

Eligibility criteria:
inclusion criteria: * adults with amblyopia (age \>15 years) * amblyopia: interocular visual acuity difference of at least 0.1 logmar * all forms of amblyopia: strabismic, anisometropic, refractive, deprivative, meridional amblyopia exclusion criteria: * any ocular pathological conditions (eg macula abnormalities, glaucoma), nystagmus

Keywords: amblyopia treatment neural plasticity perceptual learning vision therapy spatial vision video games occlusion therapy
transdermal testosterone nanoemulsion in women libido

Conditions: Menopause

Summary: this is a double-blind, randomized, placebo-controlled study. seventy women, aged 35-75 years, with treatment-emergent loss of libido will be randomly allocated to the treatment with a transdermal nanoemulsion of testosterone (500mcg) delivering 300 mcg of testosterone/day or an identical placebo nanoemulsion (pla) for 12 weeks.

the aim of this study is to investigate the efficacy of transdermal testosterone nanoemulsion (tnt) as a treatment for ssri/snri-emergent loss of libido. the primary outcome measures to be evaluated is the change in the sabbatsberg sexual self-rating scale (sss) total score over 12 weeks. the 4-week frequency of satisfactory sexual events (sses) and the female sexual distress scale-revised (fsds-r) will be also evaluate.

Eligibility criteria:
inclusion criteria: * a body mass index between 18 and 27 kg/m2; * diminished libido; * sexual behavior complaints; * no evidence of severe clinical depression; * general good health based on history and physical examination. exclusion criteria: * a past history of neurological disorder; * poor feelings for their partner; * had received pharmacotherapy for depression within 8 weeks before screening * taking medication known to interfere with normal sexual function (such as α-blockers and β-blockers); * recent psychiatric or systemic illness; * uncontrolled hypertension (blood pressure\>160/95mmhg), * unstable cardiovascular disease, * genital bleeding; * use of psychoactive medications, alcohol excess consumption or any other drug abuse; * women who had under gone treatment for acne, depression, dyspareunia.
treatment outcome of short implant assisted mandibular overdenture

Conditions: Atrophy of Edentulous Mandibular Alveolar Ridge

Summary: this study evaluates the use of short dental implants to support mandibular overdenture together with the use of laser therapy for treatment of patients with atrophic ridges. all participants will receive laser therapy; half of participants will receive two short implants and the other half will receive four short implants.

the conventional solution to complete edentulism is the use of complete removable dentures. one negative effect of edentulism is resorption of the edentulous ridge over time. construction of a successful mandibular complete denture for patients with advanced mandibular ridge resorption is often difficult and on some occasions virtually impossible. it has been proved that when implants are placed, bone gets stimulated resulting in minimal bone loss. but anatomic limitations to implant placement have been observed in atrophic ridges, so short implants introduced as a recent alternative to aggressive surgical procedures proposed to compensate for tissue deficiency. also, low level laser therapy (lllt) has proven success in improving implant stability which is very crucial in short implants. thus, the purpose of this study is to evaluate and compare the treatment outcome of mandibular overdenture assisted by two short implants versus that assisted by four short implants in combination with lllt.

Eligibility criteria:
inclusion criteria: * completely edentulous patients. * patients with mandibular resorbed edentulous ridge. * medically fit patients with no systemic conditions. * class i ridge relation. * adequate zone of keratinized mucosa. exclusion criteria: * metabolic bone disease or unstable systemic condition. * heavy smokers. * a history of radiotherapy in the head and neck region. * physical or mental disability. * temporomandibular and neuromuscular disorders.
project milano: connections between patients with brain tumors and their pets: an analysis of concerns and needs

Conditions: Brain (Nervous System) Cancers

Summary: context and problem in france, 61% of households own a pet, highlighting the significant role pets play in the daily lives. patients diagnosed with brain tumors face specific challenges that may affect their ability to care their pets, including: * progressive neurological deficits (cognitive and/or motor), limiting their autonomy, * a life-threatening prognosis. in this context, the well-being of pets when their owner's health deteriorates becomes a critical concern. indeed: * social isolation and the progressive loss of physical and cognitive abilities complicate pet care, particularly during prolonged hospitalizations or in the event of death, * the lack of appropriate facilities and care solutions causes stress for pets, who are often unprepared for such transitions, and adds to the emotional burden on patients. why focus on patients with brain tumors? * these patients have specific needs due to the rapid progression of their condition, * a local study showed that 12% of patients with gliomas live alone, a significantly higher rate than in other cancer types. patients who live alone are particularly exposed to issues related to their pet's future, * given the high morbidity and mortality associated with brain tumors, proactive planning for pet care is particularly urgent.


Eligibility criteria:
inclusion criteria: * patients diagnosed with a brain tumor. * patients who own at least one pet. exclusion criteria: * patients who decline to participate in the study. * patients unable to complete the questionnaire.

Keywords: brain tumors glioma patients pet care emotional burden
amniotic umbilical cord particulate during total knee arthroplasty

Conditions: Osteoarthritis: Joint Replacement Surgery

Summary: total knee arthroplasty (tka) is the most common joint replacement surgery and its incidence is expected to increase 673% to 3.48 million procedures annually by 2030. after more than 20 years of follow-up data, tka is confirmed to be an effective treatment for knee osteoarthritis, however, postoperative pain management continues to be a challenge despite advances in surgical techniques and anesthetic practice to minimize discomfort and enhance recovery. this acute post-surgical pain caused by extensive tissue damage and inflammation in tka leads to restricted post-operative knee range of motion (rom) and ability to mobilize.


Eligibility criteria:
inclusion criteria: 1. male or female, greater than 18 years of age 2. primary diagnosis of unilateral osteoarthritis of the knee 3. scheduled to undergo primary, unilateral tka 4. asa physical status 1, 2, or 3 exclusion criteria: 1. patient has concurrent painful physical condition not strictly related to the knee surgery that may require analgesic treatment (such as nsaids or opioid) that may confound postsurgical assessments as determined by the investigator 2. patient on chronic daily narcotic medication for knee pain based on medical history and florida prescription drug monitoring program (e-forcse) 3. allergy or contraindication to any of the study medications 4. patient reported renal impairment based on medical history 5. bodyweight less than 50 kg (110 pounds) or a body mass index greater than 40 kg/m2 6. history of previous fracture or open surgery on the knee being considered for tka 7. history of patellar instability, e.g., valgus deformity 8. history of inflammatory arthropathy (e.g., rheumatoid arthritis, lupus, etc.) 9. use of cryoneurolysis, or cryoanalgesia, including iovera® device (myoscience, fremont, ca) on the operative knee within the last 6 months or planned during study duration 10. any neurologic disorder or psychiatric disorder (e.g., parkinson's multiple sclerosis, etc.) that might impact postsurgical pain or confound postsurgical assessments 11. planned use of intra-articular steroid injections during the study. 12. received any local anesthetic within 7 days of the planned tka procedure aside from those part of the protocol 13. planned use of potent inhalational agents or peripheral nerve block (e.g., femoral nerve block) 14. current or planned use of neuraxial (epidural or intrathecal) opioids 15. received administration of an investigational drug within 30 days prior to study, and/or has planned administration of another investigational product or procedure during participation in this study 16. history of suspected, or known, misuse, abuse, dependence of opioid analgesics, illicit drugs, prescription medicines, or alcohol within the past 2 years 17. currently pregnant, nursing, or planning to become pregnant during the study
the role of proprioceptive deficits and psychosocial factors in pregnancy-related pelvic girdle pain: a follow-up study

Conditions: Pelvic Girdle Pain; Low Back Pain

Summary: a large proportion of pregnant women develop pregnancy-related low back and/or pelvic girdle pain (ppgp), which often does not recover spontaneously postpartum. as a result, 10% of women with ppgp still reports complaints a decade after delivery. the prevention and treatment of ppgp are thus crucial. however, the underlying mechanisms of ppgp are still poorly understood. the main objective of this study is to investigate whether lumbar proprioceptive deficits, a disturbed body perception at the lumbar spine and psychosocial factors (incl. pain-related fear of movement, depression, anxiety and stress) are associated with (1) a reduced postural control and (2) the development and/or persistence of ppgp in multiparous women during the first and third trimester of pregnancy, and six weeks and six months postpartum.


Eligibility criteria:
inclusion criteria: * singleton pregnancy * pregnant of second child or more than second child * no current ppgp or did not have ppgp during current pregnancy * willing to provide written informed consent exclusion criteria: * pregnant for more than 14 weeks * having current ppgp or having had ppgp during the current pregnancy * history of surgery/major trauma to spine, pelvis and/or lower limbs, * specific balance or vestibular disorders * spinal deformities * rheumatic disease * neurological abnormalities (e * hyperemesis gravidarum * acute ankle problems * pre-existing disorders that could interfere with the course of pregnancy (e.g., hypertension, kidney disease, coagulation disorders) * (a history of) psychiatric disorders * non-dutch speaking

Keywords: postural control body perception psychosocial factors